AAN 2022 | Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the long-term efficacy and safety results from the Phase III CHAMPION MG open-label extension (NCT03920293) of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR Ab+ gMG). Ravulizumab response was seen quite rapidly, and the agent demonstrated sustained improvements in symptoms and was well tolerated for up to 1 year in adults with AChR Ab+ gMG. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.